Compare Amgen, Inc. (AMGN) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs NEOS S&P 500 High Income ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while NEOS S&P 500 High Income ETF trades at $53.61. The key difference: Amgen, Inc. pays a 2.77% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | SPYI | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $388.16 | $54.07 |
52-Week Low | $271.18 | $47.98 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SPYI trades at $53.70, up 0.36% on the day, with a bullish technical signal driven by moving averages and strong support at $53. The ETF has grown to over $10 billion in assets, highlighted by consistent monthly dividends and a yield near 12%. Recent news emphasizes its appeal for income-focused investors seeking S&P 500 exposure with reduced volatility.
Outlook remains positive due to robust investor inflows and a covered-call strategy that balances income with upside participation. Key risks include fee erosion over time and market sensitivity, but SPYI's diversification and high yield position it as a core holding for retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
